Загрузка...
Biosimilars in rheumatology: what the clinician should know
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalenc...
Сохранить в:
| Опубликовано в: : | RMD Open |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4613175/ https://ncbi.nlm.nih.gov/pubmed/26509046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2014-000010 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|